Ligand Pharmaceuticals LGND Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues and income by Product | ||||||
| Captisol | $8.65M+11.0% | $7.79M-27.0% | $10.67M+28.8% | $8.29M-38.4% | $13.46M+70.0% | |
| Capvaxive | $1.97M-47.0% | $3.72M+16.0% | $3.21M+42.5% | $2.25M+154% | $885K+363% | |
| Contract revenue | $110K-99.8% | $60.43M+46,031% | $131K-93.2% | $1.93M-56.1% | $4.38M+116% | |
| Filspari | $11.32M+2.8% | $11.01M+21.3% | $9.08M+38.0% | $6.58M+24.1% | $5.3M+11.0% | |
| Kyprolis | $6.74M— | —— | $11.62M+32.0% | $8.8M+86.4% | $4.72M— | |
| Ohtuvayre inventors | $3.05M— | —— | —— | —— | $0— | |
| Ohtuvayre | $2.99M— | —— | —— | —— | $1.41M— | |
| Other | $3.76M— | —— | $3.42M-37.1% | $5.43M+48.0% | $3.67M— | |
| Qarziba | $6.3M-2.1% | $6.44M+7.7% | $5.98M+1.5% | $5.89M+8.1% | $5.44M-16.2% | |
| Rylaze | $3.22M— | —— | $3.56M+24.2% | $2.86M-8.2% | $3.12M— | |
| Teriparatide injection | $1.32M— | —— | $2.63M+14.5% | $2.3M+92.9% | $1.19M— | |
| Vaxneuvance | $1.61M+12.1% | $1.44M-29.6% | $2.04M-22.9% | $2.64M+106% | $1.29M+5.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ligand Pharmaceuticals break its business down?
- Ligand Pharmaceuticals (LGND) reports total revenues and income by product across 12 parts — Captisol, Capvaxive, Contract revenue, Filspari and Kyprolis. Each is extracted from the segment footnotes and tracked over time.
- Where does Ligand Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ligand Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.